Enzymes & Kinetics

Enzymes & Kinetics

Part 1 of 4 — Enzyme Fundamentals: Catalysis & Specificity

What Enzymes Do (and Don't Do)

Enzymes are biological catalysts (mostly proteins; some catalytic RNAs — ribozymes, including the ribosome's peptidyl transferase center). A catalyst:

• Lowers activation energy ($E_a$) by stabilizing the transition state
• Speeds up both forward and reverse reactions equally
• Is regenerated unchanged after each cycle

A catalyst does NOT change:

• $\Delta G$ of the reaction (thermodynamics untouched)
• $K_{eq}$ or the final equilibrium position
• Whether a reaction is spontaneous

The rate boost comes from the Arrhenius relationship: rate $\propto e^{-E_a/RT}$, so even a modest drop in $E_a$ multiplies the rate enormously.

Binding Models

The deepest statement of catalysis: enzymes bind the transition state more tightly than the substrate itself. (This is why transition-state analogs are extraordinarily potent inhibitors.)

Catalytic Strategies

• Acid-base catalysis: His (pKa ~6) donates/accepts protons
• Covalent catalysis: transient enzyme-substrate covalent bond (e.g., serine protease acyl-enzyme intermediate via the Ser-His-Asp catalytic triad)
• Electrostatic/metal-ion catalysis: metal cations stabilize negative charge or activate water (e.g., $Zn^{2+}$ in carbonic anhydrase lowers bound water's pKa so a $Zn$-bound hydroxide attacks CO$_2$)
• Proximity and orientation: holding substrates next to each other in the right geometry

Cofactors and Coenzymes

Enzyme Classes (EC) — Recognize the Reaction Type

MCAT trap: kinase (transfers phosphate from ATP to substrate) vs. phosphatase (hydrolyzes phosphate off) vs. phosphorylase (attacks a bond with inorganic phosphate).

Enzyme Fundamentals 🎯

Key Takeaways — Part 1

• Enzymes lower $E_a$ by stabilizing the transition state; $\Delta G$, $K_{eq}$, and spontaneity never change
• Induced fit > lock and key; transition-state analogs = ultra-potent inhibitors
• Catalytic toolkit: acid-base (His), covalent (Ser proteases), metal ions, proximity/orientation
• Apoenzyme + cofactor = holoenzyme; coenzymes are vitamin-derived (NAD$^+$, FAD, CoA, TPP, PLP, biotin)
• Know the six EC classes and the kinase/phosphatase/phosphorylase distinction

Worked Examples — Catalysis Concepts

Question: For an exergonic reaction ($\Delta G^{\circ\prime} = -20$ kJ/mol) with $E_a = 80$ kJ/mol uncatalyzed, sketch what changes when an enzyme is added.

Solution:

1. Reactant and product energy levels: unchanged — so $\Delta G^{\circ\prime}$ stays −20 kJ/mol.
2. The peak (transition state) drops: $E_a$ might fall from 80 to, say, 30 kJ/mol.
3. Both the forward barrier and reverse barrier decrease by the same absolute amount at the peak; their difference (still −20) is preserved.

MCAT Strategy: On any energy-diagram question, the enzyme only moves the hump, never the endpoints.

Question: An enzyme preparation loses activity after dialysis against buffer, and activity is restored by adding back a small filtrate fraction that is heat-stable. Is the missing component more likely a protein subunit or a coenzyme?

Solution:

1. Dialysis removes SMALL molecules — a loosely bound cofactor/coenzyme dialyzes away; protein subunits generally do not.
2. Heat stability: proteins denature with heat; small organic cofactors and metal ions survive boiling.
3. Conclusion: a dialyzable, heat-stable coenzyme (or metal ion) was removed, converting holoenzyme to inactive apoenzyme.

MCAT Strategy: "Small, dialyzable, heat-stable" is exam code for cofactor/coenzyme.

Question: Classify each: (a) pyruvate + CO$_2$ + ATP → oxaloacetate + ADP + P$_i$; (b) glucose-6-phosphate + H$_2$O → glucose + P$_i$; (c) lactate + NAD$^+$ → pyruvate + NADH.

Solution:

1. (a) Joins CO$_2$ to pyruvate at the expense of ATP → ligase (pyruvate carboxylase; note biotin cofactor for carboxylations).
2. (b) Cleaves a phosphate ester using water → hydrolase (glucose-6-phosphatase).
3. (c) Electron transfer to NAD$^+$ → oxidoreductase (lactate dehydrogenase).

MCAT Strategy: Scan for the signature: ATP + joining = ligase; water = hydrolase; NAD$^+$/FAD = oxidoreductase; group moved between molecules = transferase.

Enzymes & Kinetics

Part 2 of 4 — Michaelis-Menten Kinetics

The Model

For $E + S \rightleftharpoons ES \rightarrow E + P$, the initial velocity at substrate concentration $[S]$ is:

$v_0 = \frac{V_{max}[S]}{K_m + [S]}$

How to Read $K_m$

$K_m$ is an inverse measure of apparent affinity: a LOW $K_m$ means the enzyme reaches half-maximal speed at low substrate — high affinity. $K_m$ is a property of the enzyme-substrate pair and does not change when you add more enzyme. $V_{max}$, by contrast, is directly proportional to enzyme concentration.

Limiting behaviors you should be able to derive:

• When $[S] \ll K_m$: $v_0 \approx (V_{max}/K_m)[S]$ — rate is roughly first order in substrate.
• When $[S] \gg K_m$: $v_0 \approx V_{max}$ — rate is zero order in substrate (saturated; adding substrate does nothing).
• When $[S] = K_m$: $v_0 = V_{max}/2$ by definition.

Catalytic Efficiency

$\text{efficiency} = \frac{k_{cat}}{K_m}$

This ratio compares enzymes (or one enzyme's preference among substrates) at low, physiological substrate levels. Its ceiling is the diffusion limit — the enzyme cannot convert substrate faster than substrate can collide with it; enzymes near it (catalase, carbonic anhydrase) are "catalytically perfect."

The diffusion limit is roughly $10^{8}$-$10^{9}\ M^{-1}s^{-1}$.

The Lineweaver-Burk (Double-Reciprocal) Plot

Taking reciprocals linearizes the hyperbola:

$\frac{1}{v_0} = \frac{K_m}{V_{max}}\cdot\frac{1}{[S]} + \frac{1}{V_{max}}$

• y-intercept $= 1/V_{max}$ (higher intercept = LOWER $V_{max}$)
• x-intercept $= -1/K_m$ (closer to zero = LARGER $K_m$)
• slope $= K_m/V_{max}$

The MCAT loves asking you to compare two lines and infer what changed. Anchor yourself on the intercepts, not the slopes.

Physiological Contrast: Hexokinase vs. Glucokinase

Hexokinase (most tissues) has a LOW $K_m$ — it works at full speed even at low glucose. Glucokinase (liver, pancreatic beta cells) has a HIGH $K_m$ near fasting blood glucose — its rate tracks blood glucose, letting the liver respond proportionally after a meal. Same reaction, different kinetics, different job.

Michaelis-Menten Kinetics 🎯

Key Takeaways — Part 2

• $v_0 = V_{max}[S]/(K_m + [S])$; at $[S] = K_m$, $v_0 = V_{max}/2$
• Low $K_m$ = high apparent affinity; $K_m$ ignores enzyme amount, $V_{max}$ scales with it ($V_{max} = k_{cat}[E]_t$)
• $k_{cat}/K_m$ = efficiency at low substrate; diffusion limit defines "catalytic perfection"
• Lineweaver-Burk: y-intercept $1/V_{max}$, x-intercept $-1/K_m$, slope $K_m/V_{max}$
• Hexokinase (low $K_m$, always on) vs. glucokinase (high $K_m$, glucose sensor) is the classic physiological application

• Low-yield extras: the numerical diffusion limit, roughly $10^{8}$-$10^{9}\ M^{-1}s^{-1}$

Worked Examples — Kinetics Calculations

Question: An enzyme has $V_{max} = 120$ $\mu$mol/min and $K_m = 4$ mM. What is $v_0$ at $[S] = 12$ mM?

Solution:

1. $v_0 = V_{max}[S]/(K_m + [S]) = 120 \times 12/(4 + 12)$
2. $= 1440/16 = 90$ $\mu$mol/min
3. Sanity check: 12 mM is $3K_m$, and $3/(1+3) = 3/4$ of $V_{max}$ — indeed $0.75 \times 120 = 90$.

MCAT Strategy: Memorize the fraction shortcut: at $[S] = nK_m$, $v_0 = \frac{n}{n+1}V_{max}$. At $K_m$: 1/2. At $4K_m$: 4/5. At $9K_m$: 90%.

Question: A double-reciprocal plot has y-intercept $0.01$ (min/$\mu$mol) and x-intercept $-0.5$ (1/mM). Find $V_{max}$ and $K_m$.

Solution:

1. y-intercept $= 1/V_{max} = 0.01$, so $V_{max} = 100$ $\mu$mol/min.
2. x-intercept $= -1/K_m = -0.5$, so $K_m = 2$ mM.
3. Slope check: $K_m/V_{max} = 2/100 = 0.02$ mM·min/$\mu$mol — consistent.

MCAT Strategy: Invert and drop the sign. Most errors come from forgetting that intercepts are RECIPROCALS: a small y-intercept means a big $V_{max}$.

Question: A point mutation in an enzyme's substrate-binding pocket (far from the catalytic residues) is characterized kinetically. Predict the likely changes in $K_m$ and $k_{cat}$, and what the Lineweaver-Burk plot would show versus wild type.

Solution:

1. Weakened substrate binding raises $K_m$ (more substrate needed to reach half-saturation).
2. The chemistry step is untouched, so $k_{cat}$ (and $V_{max}$ at fixed enzyme) is roughly unchanged.
3. Plot: same y-intercept, x-intercept pulled toward the origin, steeper slope — the same signature as a competitive inhibitor, but permanent.

MCAT Strategy: Map mutations to parameters: binding-site changes move $K_m$; catalytic-residue changes move $k_{cat}$. A passage giving you a kinetics table is really asking which part of the enzyme the perturbation touched.

Enzymes & Kinetics

Part 3 of 4 — Enzyme Inhibition

Reversible Inhibition — The Big Three (Plus Mixed)

The Logic Behind the Table (Don't Memorize Blindly)

• Competitive: the inhibitor and substrate fight for the same site. Flooding with substrate outcompetes the inhibitor, so $V_{max}$ is reachable — it just takes more substrate (higher apparent $K_m$). Statins (resemble HMG-CoA) and methotrexate (resembles dihydrofolate) are classic drugs.
• Noncompetitive: the inhibitor binds an allosteric site with equal affinity whether or not substrate is bound. It effectively removes a fraction of enzyme from action — like lowering $[E]$ — so $V_{max}$ falls but substrate binding to the remaining enzyme ($K_m$) is unchanged.
• Uncompetitive: the inhibitor binds ONLY the ES complex, locking substrate on the enzyme. This pulls the $E + S \rightleftharpoons ES$ equilibrium toward ES (apparent $K_m$ DROPS — looks like higher affinity) while blocking turnover ($V_{max}$ drops). More substrate makes it WORSE, not better.

Lineweaver-Burk Signatures

• Competitive: lines intersect on the y-axis (same $1/V_{max}$).
• Noncompetitive: lines intersect on the x-axis (same $-1/K_m$).
• Uncompetitive: parallel lines (same slope $K_m/V_{max}$; both parameters fall by the same factor).

Irreversible Inhibition

Irreversible inhibitors covalently modify the enzyme (or bind so tightly they never leave). Activity returns only when the cell synthesizes new enzyme.

• Aspirin acetylates a serine in cyclooxygenase.
• Organophosphates (nerve agents, some pesticides) phosphorylate the active-site serine of acetylcholinesterase.
• Penicillin covalently traps the bacterial transpeptidase — a "suicide substrate" (mechanism-based inhibitor) that the enzyme itself activates.

Kinetically, irreversible inhibition lowers $V_{max}$ over time because functional $[E]$ falls; it is distinguished experimentally by dilution or dialysis — reversible inhibition washes out, covalent inhibition does not.

A Note on In-Vivo Relevance

Uncompetitive and mixed inhibitors are pharmacologically attractive: a competitive inhibitor's effect fades as the blocked pathway backs up substrate, but an uncompetitive inhibitor gets no such relief — the accumulating substrate actually helps it.

Enzyme Inhibition 🎯

Key Takeaways — Part 3

• Competitive: binds free E at active site; $K_m$ up, $V_{max}$ same; beaten by substrate; LB lines meet on y-axis
• Noncompetitive: binds E and ES equally at allosteric site; $V_{max}$ down, $K_m$ same; LB lines meet on x-axis
• Uncompetitive: binds ES only; BOTH $K_m$ and $V_{max}$ down; parallel LB lines; worsened by more substrate
• Mixed: unequal E/ES binding; $V_{max}$ down, $K_m$ either direction
• Irreversible = covalent (aspirin, organophosphates, penicillin); survives dialysis; recovery needs new enzyme synthesis

Worked Examples — Diagnosing Inhibitors

Question: Without inhibitor: $K_m = 5$ mM, $V_{max} = 200$ units. With inhibitor: apparent $K_m = 2.5$ mM, apparent $V_{max} = 100$ units. Classify the inhibitor.

Solution:

1. $V_{max}$ fell (200 to 100), so it is not competitive.
2. Apparent $K_m$ also FELL — and by the same factor of 2 as $V_{max}$.
3. Both parameters reduced by the same factor = uncompetitive inhibition (parallel Lineweaver-Burk lines; the ratio $K_m/V_{max}$ is unchanged at 0.025).

MCAT Strategy: Compute the ratio $K_m/V_{max}$ with and without inhibitor. Unchanged ratio = uncompetitive. $K_m$ unchanged alone = noncompetitive. $V_{max}$ unchanged alone = competitive.

Question: Drug X competitively inhibits enzyme 2 of a linear pathway (A to B to C). After dosing, the concentration of B rises 20-fold. What happens to the drug's inhibition of enzyme 2 over time, and how would an uncompetitive inhibitor differ?

Solution:

1. B is enzyme 2's substrate. As B accumulates, it increasingly outcompetes the competitive drug — inhibition weakens (the pathway partially "self-rescues").
2. An uncompetitive inhibitor binds only the ES complex. More substrate means MORE ES complex, so accumulation of B would maintain or even enhance inhibition.
3. This is why medicinal chemists often prefer uncompetitive/mixed inhibitors for enzymes whose substrates build up.

MCAT Strategy: In pathway questions, always ask what happens to the inhibited enzyme's substrate level and feed that back into the inhibition type.

Question: An enzyme preparation loses 90% activity when incubated with compound Z. Propose a simple experiment to determine whether Z is a tight-binding reversible inhibitor or a covalent irreversible one.

Solution:

1. Dilute or dialyze the enzyme-Z mixture extensively, then re-assay.
2. Reversible inhibitor: dissociates and washes away; activity returns toward 100%.
3. Irreversible inhibitor: the covalent adduct stays; activity remains ~10% after dialysis. (Confirmation: mass spectrometry showing an enzyme mass increase equal to the adduct.)

MCAT Strategy: "Does activity recover after dialysis/dilution?" is the standard experimental discriminator; activity that keeps falling with incubation time at a fixed inhibitor concentration also hints at covalent chemistry.

Enzymes & Kinetics

Part 4 of 4 — Regulation, Allostery & MCAT Integration

Allosteric Enzymes Break Michaelis-Menten

Allosteric enzymes are typically multi-subunit proteins whose velocity curve is sigmoidal, not hyperbolic. Substrate binding at one site raises the affinity of the others (positive cooperativity), switching the enzyme between a low-affinity T state and high-affinity R state.

• Homotropic effector: the substrate itself (cooperativity).
• Heterotropic effectors: other molecules binding regulatory sites. Activators shift toward R; inhibitors shift toward T.
• Because the curve is sigmoidal, we speak of $K_{0.5}$ rather than $K_m$; small changes in substrate near $K_{0.5}$ produce large rate changes — allosteric enzymes are metabolic switches, not dimmers.

Hemoglobin logic transfers directly: the oxygen saturation curve is sigmoidal for the same reason, and 2,3-BPG, H$^+$, and CO$_2$ act as heterotropic T-state stabilizers (right shift).

Covalent Modification & Zymogens

Feedback Inhibition

In a pathway $A \rightarrow B \rightarrow C \rightarrow D$, the end product D typically allosterically inhibits the first committed step ($A \rightarrow B$). This prevents wasted flux and intermediate buildup. Classic example: ATP and citrate inhibit phosphofructokinase-1, while AMP activates it — glycolysis throttles to energy demand.

Environmental Effects on Rate

• Temperature: rate rises (~doubles per 10 degrees C) until heat denatures the enzyme; activity then collapses. Human enzymes peak near 37 degrees C.
• pH: each enzyme has an optimum reflecting the protonation states its mechanism needs — pepsin ~2 (stomach), trypsin ~8 (intestine). Off-optimum pH first alters charge states, then denatures.

• A further example: alkaline phosphatase works best near pH 9.

Reading Kinetics Experiments (Passage Skills)

1. Identify what was varied (substrate? inhibitor? enzyme? mutation?) and what was measured ($v_0$? product at fixed time?).
2. Compare $K_m$-like and $V_{max}$-like behavior before assigning inhibitor type or mutation location.
3. Sigmoidal curve, Hill coefficient > 1, or "cooperative" language = allosteric, multi-subunit thinking.
4. Watch for assays run at a single substrate concentration — changes there can reflect either affinity or turnover; you cannot tell without a full curve.

Regulation & Integration 🎯

Key Takeaways — Part 4

• Sigmoidal velocity curve = cooperativity = multi-subunit allosteric enzyme (T/R states, $K_{0.5}$); same logic as hemoglobin
• Heterotropic effectors bind regulatory sites: activators favor R, inhibitors favor T (feedback inhibition hits the first committed step)
• Phosphorylation = fast reversible switch (phosphorylase ON / synthase OFF is the reciprocal pattern); zymogen cleavage = irreversible activation
• Temperature and pH optima: activity falls off-optimum by ionization changes, then denaturation
• Passage skill: never assign inhibitor type or mutation effect from a single-substrate-concentration data point

• Low-yield extras: alkaline phosphatase's pH optimum (~9)

Worked Examples — MCAT-Style Integration

Question: In E. coli, ATCase (aspartate transcarbamoylase) catalyzes the committed step of pyrimidine synthesis. Adding CTP shifts its sigmoidal curve right (higher $K_{0.5}$); adding ATP shifts it left. Explain the metabolic logic.

Solution:

1. CTP is the pathway's END PRODUCT: high CTP means pyrimidines are plentiful, so CTP feedback-inhibits (stabilizes T state, right shift).
2. ATP is a purine: high ATP signals abundant energy and a need to balance purine/pyrimidine pools, so ATP activates (stabilizes R state, left shift).
3. Both act heterotropically at regulatory subunits — neither touches the catalytic site.

MCAT Strategy: Right shift = inhibition (more substrate needed); left shift = activation. Then ask "why would the cell want this?" — the answer is nearly always feedback economy or pathway balancing.

Question: One hormone-bound receptor activates 10 molecules of kinase A; each kinase A activates 10 of kinase B; each kinase B activates 10 phosphorylase molecules, each producing 100 product molecules per second. How many product molecules per second result from ONE receptor?

Solution:

1. Kinase A: $10$; kinase B: $10 \times 10 = 100$; phosphorylase: $100 \times 10 = 1000$ active enzymes.
2. Product: $1000 \times 100 = 10^{5}$ molecules per second.
3. This multiplicative amplification is why signaling uses kinase cascades rather than direct enzyme activation.

MCAT Strategy: Cascade math is pure multiplication of the per-step factors; the exam wants you to recognize amplification as the PURPOSE of multi-step cascades.

Question: A passage reports that mutant enzyme M has normal $k_{cat}$ but 10-fold higher $K_m$ than wild type, and that drug D lowers wild-type $V_{max}$ by half without changing $K_m$. A patient homozygous for M is treated with D. Predict the combined kinetic parameters relative to untreated wild type.

Solution:

1. Mutation M: $K_m$ 10-fold up (weaker substrate binding), $V_{max}$ normal.
2. Drug D is noncompetitive ($V_{max}$ halved, $K_m$ untouched) and acts at an allosteric site, independent of the substrate pocket.
3. Combined: $K_m$ ~10-fold above wild type (from M) AND $V_{max}$ ~half (from D). The effects stack because they act on different parts of the enzyme.

MCAT Strategy: Treat independent perturbations as independent: binding-site changes move $K_m$, allosteric/noncompetitive effects move $V_{max}$, and they combine without interference unless the passage says the sites interact.